Sisram Medical Management

Management criteria checks 2/4

Sisram Medical's CEO is Lior Dayan, appointed in Jun 2017, has a tenure of 7.42 years. total yearly compensation is $1.53M, comprised of 56.6% salary and 43.4% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth HK$3.34M. The average tenure of the management team and the board of directors is 1.8 years and 7.3 years respectively.

Key information

Lior Dayan

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage56.6%
CEO tenure7.4yrs
CEO ownership0.2%
Management average tenure1.8yrs
Board average tenure7.3yrs

Recent management updates

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Jun 17
Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Recent updates

What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You

Oct 07
What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Aug 23
Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet

Jul 24
Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Jun 17
Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Apr 21
Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Mar 28
Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Mar 05
Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Jan 23
Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Dec 29
Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Nov 09
Is Sisram Medical (HKG:1696) Using Too Much Debt?

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Oct 19
Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

Sep 18
At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Aug 14
Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Jun 16
Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

May 30
Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Apr 19
Is Sisram Medical (HKG:1696) Using Too Much Debt?

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Mar 01
Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Jan 12
Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Dec 21
Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Dec 01
Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Oct 14
Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Sep 28
Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Aug 25
These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Aug 01
Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

May 19
These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?

May 03
Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?

If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late

Apr 11
If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late

Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital

Mar 17
Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital

Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?

Nov 22
Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?

Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Aug 22
Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital

Jul 27
Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital

Here's Why We Think Sisram Medical Ltd's (HKG:1696) CEO Compensation Looks Fair

Jun 24
Here's Why We Think Sisram Medical Ltd's (HKG:1696) CEO Compensation Looks Fair

CEO Compensation Analysis

How has Lior Dayan's remuneration changed compared to Sisram Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$28m

Dec 31 2023US$2mUS$863k

US$31m

Sep 30 2023n/an/a

US$35m

Jun 30 2023n/an/a

US$38m

Mar 31 2023n/an/a

US$39m

Dec 31 2022US$3mUS$1m

US$40m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$35m

Mar 31 2022n/an/a

US$33m

Dec 31 2021US$2mUS$767k

US$31m

Sep 30 2021n/an/a

US$28m

Jun 30 2021n/an/a

US$24m

Mar 31 2021n/an/a

US$19m

Dec 31 2020US$769kUS$596k

US$13m

Sep 30 2020n/an/a

US$13m

Jun 30 2020n/an/a

US$13m

Mar 31 2020n/an/a

US$17m

Dec 31 2019US$759kUS$606k

US$21m

Sep 30 2019n/an/a

US$22m

Jun 30 2019n/an/a

US$24m

Mar 31 2019n/an/a

US$23m

Dec 31 2018US$884kUS$560k

US$22m

Sep 30 2018n/an/a

US$18m

Jun 30 2018n/an/a

US$14m

Mar 31 2018n/an/a

US$12m

Dec 31 2017US$829kUS$361k

US$11m

Compensation vs Market: Lior's total compensation ($USD1.53M) is above average for companies of similar size in the Hong Kong market ($USD359.96K).

Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.


CEO

Lior Dayan (54 yo)

7.4yrs

Tenure

US$1,526,000

Compensation

Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and its President since 2023 and is responsible for its overall and day-to-day manageme...


Leadership Team

NamePositionTenureCompensationOwnership
Yi Liu
Executive Chairman8.6yrsUS$27.00k0.053%
HK$ 890.0k
Lior Dayan
President7.4yrsUS$1.53m0.20%
HK$ 3.3m
Jiahong Li
Chief Financial Officerless than a yearno datano data
Ran Ezioni
Chief Operating Officer6.6yrsno datano data
Doron Yannai
VP of Finance1.8yrsno datano data
Nikol Lev
Chief Information Officerless than a yearno datano data
Tal Rosen
Chief Marketing Officer1.8yrsno datano data
Orit Segal
Chief People Officer1.8yrsno datano data
Eyal David
President of ROW1.8yrsno datano data
Itay Meir
EVP of R&D1.8yrsno datano data
Keith Adams
President NA1.8yrsno datano data
Qianli Fang
Company Secretary2.8yrsno datano data

1.8yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 1696's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Yi Liu
Executive Chairman8.6yrsUS$27.00k0.053%
HK$ 890.0k
Lior Dayan
President7.4yrsUS$1.53m0.20%
HK$ 3.3m
Heung Sang Fong
Independent Non-Executive Director7.3yrsUS$32.00kno data
Yifang Wu
Non-Executive Director8.1yrsno datano data
Chi Fung Chan
Independent Non-Executive Director7.3yrsUS$32.00kno data
Jenny Chen
Independent Non-Executive Director7.3yrsUS$32.00kno data
Kai Yu Liu
Independent Non-Executive Director7.3yrsUS$32.00kno data
Rongli Feng
Non-Executive Director4.3yrsno datano data

7.3yrs

Average Tenure

51.5yo

Average Age

Experienced Board: 1696's board of directors are considered experienced (7.3 years average tenure).